

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Torti Frank		2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/18/2019						
320 W 37TH STREET, 3RD FLOOR									
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				
NEW YORK, NY 10018									
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$ 7.86	12/18/2019		A		137,617		(1)	06/19/2029	Common Stock	137,617	(2)	137,617	D	
Stock Option (right to buy)	\$ 7.86	12/18/2019		A		893		(1)	07/28/2029	Common Stock	893	(3)	893	D	
Stock Option (right to buy)	\$ 8.43	12/18/2019		A		11,488		(1)	10/20/2029	Common Stock	11,488	(4)	11,488	D	
Stock Option (right to buy)	\$ 8.43	12/18/2019		A		3,765		(1)	11/19/2029	Common Stock	3,765	(5)	3,765	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Torti Frank 320 W 37TH STREET, 3RD FLOOR NEW YORK, NY 10018	X			

Signatures

/s/ W. Bradford Middlekauff, attorney-in-fact for Frank M. Torti 12/20/2019

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of \$3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

(3) In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of \$3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

(4) In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of \$4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

(5) In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of \$4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.